1. Executive Summary
2. Research Methodology
3. Respiratory Diseases
3.1 Background
3.2 Types
3.3 Asthma
3.3.1 Overview
3.3.2 Treatment
COPD
3.4.1 Overview
3.4.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease
4.2.2 Market Share by Segments
4.2.3 Market Share by Therapeutic Classes
Figure: Global Asthma & COPD Market Share by Therapeutic Classes (2018)
4.2.4 Market Share by Nations
5. Treatment
5.1 Anti-inflammatory drugs
5.1.1 Inhaled Corticosteroids (ICS)
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.2 Bronchodilator Monotherapy
5.2.1 Long Acting Beta Agonists (LABA)
5.2.1.1 Overview
5.2.1.1 Market Sizing (Actual & Forecasted)
5.2.2 Short Acting Beta Agonists (SABA)
5.2.2.1 Overview
5.2.2.2 Market Sizing (Actual & Forecasted)
5.3 Others
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Country Analysis
6.1 The US
6.1.1 Market Sizing (Actual & Forecasted)
6.2 Germany
6.2.1 Market Sizing (Actual & Forecasted)
6.3 France
6.3.1 Market Sizing (Actual & Forecasted)
6.4 Japan
6.4.1 Market Sizing (Actual & Forecasted)
6.5 China
6.5.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Connected Health Solutions
7.1.2 Higher Demand for Combination Therapies
7.1.3 Advent of Stem Cell Therapy
7.2 Growth Drivers
7.2.1 Prevalence of Respiratory Diseases
7.2.2 Environmental Pollution
7.2.3 Government Impetus
7.2.4 Rise in Number of Smokers
7.2.5 Growing Geriatric Population
7.3 Challenges
7.3.1 Stringent Regulatory Compliance
7.3.2 Patent Expiration of Drugs
7.3.3 Side-Effects of Drugs
8. Competitive Landscape
8.1 Drugs Clinical Pipeline
8.2 Financial Analysis
8.3 Market Share Analysis
9. Company Profiles
9.1 AstraZeneca plc
9.2 GlaxoSmithKline plc
9.3 F. Hoffmann-La Roche AG
9.4 Novartis AG
9.5 Merck & Co., Inc.